



FIGURE 1: Correlations and consistency between measurements of pre- and post-HD dry weight using the two devices.

MO850 CASIRIVIMAB/IMDEVIMAB IN VACCINATED CHRONIC HAEMODIALYZED PATIENTS WITH ACUTE MILD COVID-19: SAFETY AND EFFICIENCY

Matthieu Monge¹, Soledad Henriquez², Caroline Humbert³, Elsa Guiard¹, Mahmoud Allouache¹, Jean-Marc Yhuel¹, Marie Lavollay⁴, Clemence Richaud² and Afsaneh Gohari³

¹Hemodialysis, Institut Mutualiste Montsouris, Paris, France, ²Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ³Pharmacy, Institut Mutualiste Montsouris, Paris, France and ⁴Microbiology, Institut Mutualiste Montsouris, Paris, France

BACKGROUND AND AIMS: Casirivimab/imdevimab (C/I) is a combination of two neutralizing human monoclonal antibodies against the SARS-CoV-2. It has been approved for primary prophylaxis or acute SARS-CoV-2 infection in patients with a poor vaccine response. Chronic haemodialyzed (CHD) patients are a high-risk population for both severe COVID-19 and impaired vaccine response. We herein report the safety and efficiency of C/I in CHD patients with acute mild COVID-19.

METHOD: In a single-centre haemodialysis facility, all 56 CHD patients received 3 injections of anti-COVID-19 mRNA BNT162b2 vaccine, with anti-S protein antibodies response assessed 7 months after the last injection. During follow-up, patients who presented an acute mild SARS-CoV-2 infection without the need for oxygen therapy and a poor vaccine response received within 5 days after diagnosis 600mg/600mg of C/I. The combination of monoclonal antibodies was infused only once after the end of the dialysis session during 20 min. Patients were kept under surveillance during 1 h before discharge. Efficiency was assessed by RT-PCR 7 days after C/I infusion and clinical evaluation.

RESULTS: Six CHD patients had an acute COVID-19 without oxygen therapy requirement and four had a vaccine response < 264 BAU/mL. Among them three had the Delta variant (L452R mutation), and received C/I. Two of them had the opportunity to have a fourth vaccine injection, but got infected within 2 weeks after the boost. Clinical data are summarized in Table 1. No patient presented any adverse effect within the time in the dialysis facility. During follow-up, all patients remained asymptomatic and all control RT-PCR performed 7 days after infusion were negative. **CONCLUSION:** 600 mg/600 mg of C/I is a safe and efficient treatment for CHD patients with a poor vaccine humoral response presenting mild acute Delta variant COVID-19 without oxygen requirement.

Table 1. Clinical and biological data of CHD patients receiving C/I. Asymptomatic patients were warned of by their close circle to be case contact

Patient	Gender	Age	Vintage on dialysis (years)	Number of vaccine doses	Anti-S antibodies titer (BAU/mL)	Clinical presentation	Time between last vaccine and COVID-19 diagnosis (days)
1	F	91	12	3	97.8	Asymptomatic	220
2	M	76	0.5	4	237.2	Asymptomatic	11
3	M	83	4	4	4.2	Fever, chills	12